Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

L1-CAM-targeted antibody therapy and (177)Lu-radioimmunotherapy of disseminated ovarian cancer.

Fischer E, Grünberg J, Cohrs S, Hohn A, Waldner-Knogler K, Jeger S, Zimmermann K, Novak-Hofer I, Schibli R.

Int J Cancer. 2012 Jun 1;130(11):2715-21. doi: 10.1002/ijc.26321. Epub 2011 Aug 29.

2.

The soluble form of the cancer-associated L1 cell adhesion molecule is a pro-angiogenic factor.

Friedli A, Fischer E, Novak-Hofer I, Cohrs S, Ballmer-Hofer K, Schubiger PA, Schibli R, Grünberg J.

Int J Biochem Cell Biol. 2009 Jul;41(7):1572-80. doi: 10.1016/j.biocel.2009.01.006. Epub 2009 Jan 20.

PMID:
19401151
3.

Antibodies directed against L1-CAM synergize with Genistein in inhibiting growth and survival pathways in SKOV3ip human ovarian cancer cells.

Novak-Hofer I, Cohrs S, Grünberg J, Friedli A, Schlatter MC, Pfeifer M, Altevogt P, Schubiger PA.

Cancer Lett. 2008 Mar 18;261(2):193-204. Epub 2007 Dec 26.

PMID:
18155830
4.

Modification of different IgG1 antibodies via glutamine and lysine using bacterial and human tissue transglutaminase.

Mindt TL, Jungi V, Wyss S, Friedli A, Pla G, Novak-Hofer I, Grünberg J, Schibli R.

Bioconjug Chem. 2008 Jan;19(1):271-8. Epub 2007 Nov 8.

PMID:
17988081
5.

The L1 cell adhesion molecule as a target for radioimmunotherapy.

Novak-Hofer I.

Cancer Biother Radiopharm. 2007 Apr;22(2):175-84.

PMID:
17600464
6.

Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis.

Knogler K, Grünberg J, Zimmermann K, Cohrs S, Honer M, Ametamey S, Altevogt P, Fogel M, Schubiger PA, Novak-Hofer I.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):603-11.

7.
8.

Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment.

Arlt MJ, Novak-Hofer I, Gast D, Gschwend V, Moldenhauer G, Grünberg J, Honer M, Schubiger PA, Altevogt P, Krüger A.

Cancer Res. 2006 Jan 15;66(2):936-43.

9.

In vivo evaluation of 177Lu- and 67/64Cu-labeled recombinant fragments of antibody chCE7 for radioimmunotherapy and PET imaging of L1-CAM-positive tumors.

Grünberg J, Novak-Hofer I, Honer M, Zimmermann K, Knogler K, Bläuenstein P, Ametamey S, Maecke HR, Schubiger PA.

Clin Cancer Res. 2005 Jul 15;11(14):5112-20.

10.

Hepatocyte growth factor-induced ectodomain shedding of cell adhesion molecule L1: role of the L1 cytoplasmic domain.

Heiz M, Grünberg J, Schubiger PA, Novak-Hofer I.

J Biol Chem. 2004 Jul 23;279(30):31149-56. Epub 2004 May 19.

11.

Radiometal labeling of antibodies and antibody fragments for imaging and therapy.

Novak-Hofer I, Waibel R, Zimmermann K, Schibli R, Grünberg J, Chester KA, Murray A, Lo BK, Perkins AC, Schubiger PA.

Methods Mol Biol. 2004;248:481-94. No abstract available.

PMID:
14970515
12.

Targeting of renal carcinoma with 67/64Cu-labeled anti-L1-CAM antibody chCE7: selection of copper ligands and PET imaging.

Zimmermann K, Grünberg J, Honer M, Ametamey S, Schubiger PA, Novak-Hofer I.

Nucl Med Biol. 2003 May;30(4):417-27.

PMID:
12767399
13.

High-yield production of recombinant antibody fragments in HEK-293 cells using sodium butyrate.

Grünberg J, Knogler K, Waibel R, Novak-Hofer I.

Biotechniques. 2003 May;34(5):968-72.

14.

Imaging of renal carcinoma xenografts with 64Cu-labelled anti-L1-CAM antibody chCE7.

Novak-Hofer I, Honer M, Ametamey S, Grünberg J, Missimer J, Zimmermann K, Schubiger PA.

Eur J Nucl Med Mol Imaging. 2003 Jul;30(7):1066. Epub 2003 May 22. No abstract available.

PMID:
12761598
15.

Ceruloplasmin carries the anionic glycan oligo/poly alpha2,8 deaminoneuraminic acid.

Ziak M, Meier M, Novak-Hofer I, Roth J.

Biochem Biophys Res Commun. 2002 Jul 19;295(3):597-602.

PMID:
12099680
16.

Copper-67 as a therapeutic nuclide for radioimmunotherapy.

Novak-Hofer I, Schubiger PA.

Eur J Nucl Med Mol Imaging. 2002 Jun;29(6):821-30. Epub 2002 Feb 2. Review.

PMID:
12029558
17.

Peptide linkers lead to modification of liver metabolism and improved tumor targeting of copper-67-labeled antibody fragments.

Novak-Hofer I, Zimmermann K, Schubiger PA.

Cancer Biother Radiopharm. 2001 Dec;16(6):469-81.

PMID:
11789024
18.

Cleavable linkers to enhance selectivity of antibody-targeted therapy of cancer.

Kukis DL, Novak-Hofer I, DeNardo SJ.

Cancer Biother Radiopharm. 2001 Dec;16(6):457-67. Review.

PMID:
11789023
19.

A comparison of targeting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients.

Hoefnagel CA, Rutgers M, Buitenhuis CK, Smets LA, de Kraker J, Meli M, Carrel F, Amstutz H, Schubiger PA, Novak-Hofer I.

Eur J Nucl Med. 2001 Mar;28(3):359-68.

PMID:
11315605
20.

A comparison of targetting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients.

Hoefnagel CA, Rutgers M, Buitenhuis CK, Smets LA, Kraker Jd, Meli M, Carrel F, Amstutz H, Schubiger PA, Novak-Hofer I.

Eur J Nucl Med. 2001 Mar;28(3):359-68. doi: 10.1007/s002590000454.

PMID:
24623005
21.

IRIV-adjuvanted hepatitis A vaccine: in vivo absorption and biophysical characterization.

Zurbriggen R, Novak-Hofer I, Seelig A, Glück R.

Prog Lipid Res. 2000 Jan;39(1):3-18.

PMID:
10729605
22.

A triglycine linker improves tumor uptake and biodistributions of 67-Cu-labeled anti-neuroblastoma MAb chCE7 F(ab')2 fragments.

Zimmermann K, Gianollini S, Schubiger PA, Novak-Hofer I.

Nucl Med Biol. 1999 Nov;26(8):943-50.

PMID:
10708309
23.

[76Br]Bromodeoxyuridine, a potential tracer for the measurement of cell proliferation by positron emission tomography, in vitro and in vivo studies in mice.

Ryser JE, Bläuenstein P, Rémy N, Weinreich R, Hasler PH, Novak-Hofer I, Schubiger PA.

Nucl Med Biol. 1999 Aug;26(6):673-9.

PMID:
10587106
24.

Anti-neuroblastoma antibody chCE7 binds to an isoform of L1-CAM present in renal carcinoma cells.

Meli ML, Carrel F, Waibel R, Amstutz H, Crompton N, Jaussi R, Moch H, Schubiger PA, Novak-Hofer I.

Int J Cancer. 1999 Oct 29;83(3):401-8.

25.

Derivatives of 1,3,5-triamino-1,3,5-trideoxy-cis-inositol as versatile pentadentate ligands for protein labeling with Re-186/188. prelabeling, biodistribution, and X-ray structural studies.

Kramer A, Alberto R, Egli A, Novak-Hofer I, Hegetschweiler K, Abram U, Bernhardt PV, Schubiger PA.

Bioconjug Chem. 1998 Nov-Dec;9(6):691-702.

PMID:
9815162
26.

Evaluation of radioiodinated and radiocopper labeled monovalent fragments of monoclonal antibody chCE7 for targeting of neuroblastoma.

Carrel F, Amstutz H, Novak-Hofer I, Schubiger PA.

Nucl Med Biol. 1997 Aug;24(6):539-46.

PMID:
9316082
27.

Tumor uptake and metabolism of copper-67-labeled monoclonal antibody chCE7 in nude mice bearing neuroblastoma xenografts.

Novak-Hofer I, Zimmermann K, Maecke HR, Amstutz HP, Carrel F, Schubiger PA.

J Nucl Med. 1997 Apr;38(4):536-44.

28.

Experience with the iodine-123 and technetium-99m labelled anti-granulocyte antibody MAb47: a comparison of labelling methods.

Bläuenstein P, Locher JT, Seybold K, Koprivova H, Janoki GA, Mäcke HR, Hasler P, Ammann A, Novak-Hofer I, Smith A, et al.

Eur J Nucl Med. 1995 Jul;22(7):690-8.

PMID:
7498233
29.

Cellular processing of copper-67-labeled monoclonal antibody chCE7 by human neuroblastoma cells.

Novak-Hofer I, Amstutz HP, Mäcke HR, Schwarzbach R, Zimmermann K, Morgenthaler JJ, Schubiger PA.

Cancer Res. 1995 Jan 1;55(1):46-50.

30.

Internalization and degradation of monoclonal antibody chCE7 by human neuroblastoma cells.

Novak-Hofer I, Amstutz HP, Morgenthaler JJ, Schubiger PA.

Int J Cancer. 1994 May 1;57(3):427-32.

PMID:
8169006
31.

Preclinical evaluation of 67Cu-labeled intact and fragmented anti-colon carcinoma monoclonal antibody MAb35.

Smith A, Alberto R, Blaeuenstein P, Novak-Hofer I, Maecke HR, Schubiger PA.

Cancer Res. 1993 Dec 1;53(23):5727-33.

32.

Production and characterization of a mouse/human chimeric antibody directed against human neuroblastoma.

Amstutz H, Rytz C, Novak-Hofer I, Spycher M, Schubiger PA, Blaser K, Morgenthaler JJ.

Int J Cancer. 1993 Jan 2;53(1):147-52.

PMID:
8416200
33.

Large scale preparation strategy for labelling of [123I]-SCH 23982, a dopamine D1 receptor binding agent.

Beer HF, Lin S, Novak-Hofer I, Bläuenstein P, Schubiger PA.

Int J Rad Appl Instrum A. 1992 Jun;43(6):781-7.

PMID:
1319421
34.

Radioimmunolocalization of neuroblastoma xenografts with chimeric antibody chCE7.

Novak-Hofer I, Amstutz HP, Haldemann A, Blaser K, Morgenthaler JJ, Bläuenstein P, Schubiger PA.

J Nucl Med. 1992 Feb;33(2):231-6.

35.

Antibody labeling with copper-67 using the bifunctional macrocycle 4-[(1,4,8,11-tetraazacyclotetradec-1-yl)methyl]benzoic acid.

Smith-Jones PM, Fridrich R, Kaden TA, Novak-Hofer I, Siebold K, Tschudin D, Maecke HR.

Bioconjug Chem. 1991 Nov-Dec;2(6):415-21.

PMID:
1805938
36.
37.

The in vivo binding behaviour of an I-123 labelled anti-granulocytes antibody (Granuloszint).

Hasler PH, Novak-Hofer I, Bläuenstein P, Schubiger PA.

Prog Clin Biol Res. 1990;355:299-309. No abstract available.

PMID:
2281110
38.

Ribosomal protein S6 kinase and PKC in human mammary tumor cells.

Fabbro D, Novak-Hofer I, Küng W, Meyer T, Matter A, Eppenberger U.

Recent Results Cancer Res. 1989;113:41-50. No abstract available.

PMID:
2756236
39.

Assessment of the binding properties of Granuloszint.

Schubiger PA, Hasler PH, Novak-Hofer I, Bläuenstein P.

Eur J Nucl Med. 1989;15(9):605-8.

PMID:
2598956
40.

Regulation of ribosomal protein S6 kinase in human mammary tumor cells: effect of estrogen, growth factors and phorbol ester.

Novak-Hofer I, Küng W, Fabbro D, Matter A, Eppenberger U.

Experientia. 1988 Feb 15;44(2):162-6.

PMID:
3278921
42.

Identification and characterization of a mitogen-activated S6 kinase.

Jenö P, Ballou LM, Novak-Hofer I, Thomas G.

Proc Natl Acad Sci U S A. 1988 Jan;85(2):406-10.

44.

Regulation of ion channel activity by protein phosphorylation.

Lemos JR, Novak-Hofer I, Levitan IB.

Prog Brain Res. 1986;69:107-18. No abstract available.

PMID:
2451836
45.

Epidermal growth factor-mediated activation of an S6 kinase in Swiss mouse 3T3 cells.

Novak-Hofer I, Thomas G.

J Biol Chem. 1985 Aug 25;260(18):10314-9.

46.
47.

Calcium- and cyclic nucleotide-dependent protein kinases and their substrates in the Aplysia nervous system.

Novak-Hofer I, Lemos JR, Villermain M, Levitan IB.

J Neurosci. 1985 Jan;5(1):151-9.

48.
49.

Synaptic stimulation alters protein phosphorylation in vivo in a single Aplysia neuron.

Lemos JR, Novak-Hofer I, Levitan IB.

Proc Natl Acad Sci U S A. 1984 May;81(10):3233-7.

50.

Ca++/calmodulin-regulated protein phosphorylation in the Aplysia nervous system.

Novak-Hofer I, Levitan IB.

J Neurosci. 1983 Mar;3(3):473-81.

Supplemental Content

Loading ...
Support Center